JECTIVES: VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses. METHODS: A total of 144 consecutive patients were randomly treated for 8 weeks with VSL#3 at a dose of 3,600 billion CFU/day (71 patients) or with placebo (73 patients). RESULTS: In all, 65 patients in the VSL#3 group and 66 patients in the placebo group completed the study. The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63.1 vs. 40.8; per protocol (PP) P=0.010, confidence interval (CI)??(%) 0.51-0.74; intention to treat (ITT) P=0.031, CI??(%) 0.47-0.69). Significant results with VSL#3 were recorded in an improvement of three points or more in the UCDAI score (60.5% vs. 41.4%; PP P=0.017, CI??(%) 0.51-0.74; ITT P=0.046, CI??(%) 0.47-0.69) and in rectal bleeding (PP P=0.014, CI??(%) 0.46-0.70; ITT P=0.036, CI??(%) 0.41-0.65), whereas stool frequency (PP P=0.202, CI??(%) 0.39-0.63; ITT P=0.229, CI??(%) 0.35-0.57), physician's rate of disease activity (PP P=0.088, CI??(%) 0.34-0.58; ITT P=0.168, CI??(%) 0.31-0.53), and endoscopic scores (PP P=0.086, CI??(%) 0.74-0.92; ITT P=0.366, CI??(%) 0.66-0.86) did not show statistical differences. Remission was higher in the VSL#3 group than in the placebo group (47.7% vs. 32.4%; PP P=0.069, CI??(%) 0.36-0.60; ITT P=0.132, CI??(%) 0.33-0.56). Eight patients on VSL#3 (11.2%) and nine patients on placebo (12.3%) reported mild side effects. CONCLUSIONS: VSL#3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing mild-to-moderate UC who are under treatment with 5-ASA and/or immunosuppressants. Moreover, VSL#3 improves rectal bleeding and seems to reinduce remission in relapsing UC patients after 8 weeks of treatment, although these parameters do not reach statistical significance.
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study / Tursi, A; Brandimarte, G; Papa, A; Giglio, A; Elisei, W; Giorgetti, Gm; Forti, G; Morini, S; Hassan, C; Pistoia, Ma; Modeo, Me; Rodino', S; D'Amico, T; Sebkova, L; Sacca', N; DI GIULIO, Emilio; Luzza, F; Imeneo, M; Larussa, T; DI ROSA, S; Annese, V; Danese, S; Gasbarrini, A.. - In: THE AMERICAN JOURNAL OF GASTROENTEROLOGY. - ISSN 0002-9270. - STAMPA. - 105:(2010), pp. 2218-2227. [10.1038/ajg.2010.218]
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study
DI GIULIO, Emilio;
2010
Abstract
JECTIVES: VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses. METHODS: A total of 144 consecutive patients were randomly treated for 8 weeks with VSL#3 at a dose of 3,600 billion CFU/day (71 patients) or with placebo (73 patients). RESULTS: In all, 65 patients in the VSL#3 group and 66 patients in the placebo group completed the study. The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63.1 vs. 40.8; per protocol (PP) P=0.010, confidence interval (CI)??(%) 0.51-0.74; intention to treat (ITT) P=0.031, CI??(%) 0.47-0.69). Significant results with VSL#3 were recorded in an improvement of three points or more in the UCDAI score (60.5% vs. 41.4%; PP P=0.017, CI??(%) 0.51-0.74; ITT P=0.046, CI??(%) 0.47-0.69) and in rectal bleeding (PP P=0.014, CI??(%) 0.46-0.70; ITT P=0.036, CI??(%) 0.41-0.65), whereas stool frequency (PP P=0.202, CI??(%) 0.39-0.63; ITT P=0.229, CI??(%) 0.35-0.57), physician's rate of disease activity (PP P=0.088, CI??(%) 0.34-0.58; ITT P=0.168, CI??(%) 0.31-0.53), and endoscopic scores (PP P=0.086, CI??(%) 0.74-0.92; ITT P=0.366, CI??(%) 0.66-0.86) did not show statistical differences. Remission was higher in the VSL#3 group than in the placebo group (47.7% vs. 32.4%; PP P=0.069, CI??(%) 0.36-0.60; ITT P=0.132, CI??(%) 0.33-0.56). Eight patients on VSL#3 (11.2%) and nine patients on placebo (12.3%) reported mild side effects. CONCLUSIONS: VSL#3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing mild-to-moderate UC who are under treatment with 5-ASA and/or immunosuppressants. Moreover, VSL#3 improves rectal bleeding and seems to reinduce remission in relapsing UC patients after 8 weeks of treatment, although these parameters do not reach statistical significance.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
